Scientists criticise new NIH rules to cut employees' ties to industryBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7491.559-a (Published 10 March 2005) Cite this as: BMJ 2005;330:559
- Janice Hopkins Tanne
- New York
The US National Institutes of Health (NIH) has strictly limited its employees' ties to pharmaceutical and biotechnology companies. A group of leading NIH scientists, called the Assembly of Scientists, has complained that the new rules should be relaxed so as not to discourage scientists from working at the institutes.
The rules, announced by the NIH director, Dr Elias Zerhouni, say that senior scientists (about 5000 people) must not consult for pharmaceutical or biotechnology companies and must sell any shares or stock options that they or their families hold in such companies. They may not receive awards of more than $200, although the Lasker and Nobel awards are acceptable, and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial